Rohto Advanced Research Hong Kong

Rohto Advanced Research Hong Kong Limited (ARHK) was established in January 2019 by a Japanese company called ROHTO Pharmaceutical Co., Ltd (ROHTO). ARHK, in line with the strategic planning and development of regenerative medicine and related businesses, leverages ROHTO's expertise and cutting-edge technologies to contribute to scientific research and promote people's well-being. Currently, ARHK is engaged in collaborative scientific research on mesenchymal stromal cells with multiple parties in Hong Kong and globally.

We aim to expand our R&D activities worldwide and eagerly looks forward to discovering and encountering novel technologies.